Answers are grounded in this paper and cite their sources.
Vernolac is a commercially available polyherbal formulation comprising Vernonia zeylanica aerial parts, Nigella sativa seeds, Hemidesmus indicus roots, Smilax glabra rhizome, and Leucas zeylanica aerial parts. Although previous in vitro studies have demonstrated the anticancer potential of Vernolac and its active ingredients, safety data are available only for some of the plant ingredients of Vernolac. In the present study, acute and 28-day repeat-dose toxicity of Vernolac were evaluated in Wistar rats in accordance with OECD guidelines 420 and 407, respectively. Acute toxicity was investigated for 14 days after administering a single oral dose of 2000 mg/kg to 10 animals (5 males, 5 females). A repeat-dose toxicity study was conducted, in which the human equivalent therapeutic dose in rats (HED; 165 mg/kg/day), a mid-dose (2 × HED; 330 mg/kg/day), and a high dose (4 × HED; 660 mg/kg/day) were administered to three separate groups, each comprising 10 naive animals (5 males and 5 females), for a period of 28 days. In both acute and repeat-dose studies, no morbidity, mortality, changes in food and water intake, relative organ weights, microscopic changes in organs, hematological changes, or clinical signs of toxicity were observed. In the acute study, a significant increase in AST and ALT levels was observed in males. In the 28-day repeated dose study, a significant reduction in ALT was observed only in females receiving 4x HED. In summary, the LD 50 of Vernolac is above 2000 mg/kg, and a dose up to two times the therapeutic daily dose is non-toxic in Wistar rats over 28 days. The liver may be a target organ of toxicity when overdosed.
No takes yet. Share an insight, caveat, or question.
Wijerathne et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: